22,814 Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) Bought by Syon Capital LLC

Syon Capital LLC purchased a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 22,814 shares of the company's stock, valued at approximately $270,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Nordea Investment Management AB increased its holdings in Roivant Sciences by 22.5% during the fourth quarter. Nordea Investment Management AB now owns 282,834 shares of the company's stock valued at $3,306,000 after buying an additional 52,031 shares during the last quarter. Barclays PLC increased its stake in shares of Roivant Sciences by 19.7% in the 3rd quarter. Barclays PLC now owns 459,521 shares of the company's stock worth $5,302,000 after purchasing an additional 75,609 shares in the last quarter. Retirement Systems of Alabama increased its stake in Roivant Sciences by 26.9% in the 3rd quarter. Retirement Systems of Alabama now owns 530,022 shares of the company's stock worth $6,116,000 after buying an additional 112,286 shares in the last quarter. Elevate Capital Advisors LLC purchased a new stake in Roivant Sciences in the 4th quarter worth $2,116,000. Finally, Thompson Siegel & Walmsley LLC increased its stake in Roivant Sciences by 10.1% in the 4th quarter. Thompson Siegel & Walmsley LLC now owns 565,337 shares of the company's stock worth $6,688,000 after buying an additional 51,705 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ROIV shares. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Monday, April 21st.

Insiders Place Their Bets

In other news, COO Eric Venker sold 100,000 shares of the firm's stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $10.65, for a total transaction of $1,065,000.00. Following the transaction, the chief operating officer now directly owns 896,869 shares of the company's stock, valued at approximately $9,551,654.85. This trade represents a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Rakhi Kumar sold 227,500 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the transaction, the chief accounting officer now directly owns 163,264 shares in the company, valued at approximately $1,702,843.52. This trade represents a 58.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,395,541 shares of company stock valued at $14,922,538 over the last 90 days. Insiders own 7.90% of the company's stock.

Roivant Sciences Stock Performance

NASDAQ ROIV traded down $0.05 during trading on Thursday, hitting $11.58. The stock had a trading volume of 3,034,049 shares, compared to its average volume of 5,473,737. The stock has a market capitalization of $8.26 billion, a price-to-earnings ratio of -77.16 and a beta of 1.25. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $13.06. The stock has a 50 day simple moving average of $10.38 and a 200 day simple moving average of $11.14.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, sell-side analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.